BRPI0619599A2 - método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente - Google Patents
método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente Download PDFInfo
- Publication number
- BRPI0619599A2 BRPI0619599A2 BRPI0619599-7A BRPI0619599A BRPI0619599A2 BR PI0619599 A2 BRPI0619599 A2 BR PI0619599A2 BR PI0619599 A BRPI0619599 A BR PI0619599A BR PI0619599 A2 BRPI0619599 A2 BR PI0619599A2
- Authority
- BR
- Brazil
- Prior art keywords
- nuclei
- bell
- cells
- tumor
- shaped
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 48
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 11
- 230000004614 tumor growth Effects 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000008685 targeting Effects 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 59
- 102000053602 DNA Human genes 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000013043 chemical agent Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 210000004940 nucleus Anatomy 0.000 description 165
- 210000004027 cell Anatomy 0.000 description 134
- 210000001519 tissue Anatomy 0.000 description 37
- 230000004992 fission Effects 0.000 description 24
- 210000000349 chromosome Anatomy 0.000 description 20
- 208000003200 Adenoma Diseases 0.000 description 19
- 210000001072 colon Anatomy 0.000 description 19
- 230000001605 fetal effect Effects 0.000 description 17
- 208000009956 adenocarcinoma Diseases 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000001788 irregular Effects 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 9
- 230000002028 premature Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 210000002230 centromere Anatomy 0.000 description 7
- 230000016507 interphase Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000031877 prophase Effects 0.000 description 7
- 238000005204 segregation Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000010191 image analysis Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000009826 neoplastic cell growth Effects 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000004568 cement Substances 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 230000002559 cytogenic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002803 maceration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000009649 Feulgen staining Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000019506 cigar Nutrition 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000011824 nuclear material Substances 0.000 description 3
- 230000005305 organ development Effects 0.000 description 3
- 230000001855 preneoplastic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010048832 Colon adenoma Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 231100000409 cytocidal Toxicity 0.000 description 2
- 230000000445 cytocidal effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- -1 disodium hydrogen Chemical class 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101500002116 Agrotis ipsilon Tachykinin-related peptide 6 Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 238000012756 BrdU staining Methods 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000008304 DNA mechanism Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001001 laser micro-dissection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002353 nuclear lamina Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- CKRORYDHXIRZCH-UHFFFAOYSA-N phosphoric acid;dihydrate Chemical compound O.O.OP(O)(O)=O CKRORYDHXIRZCH-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74895105P | 2005-12-09 | 2005-12-09 | |
| US60/748,951 | 2005-12-09 | ||
| PCT/US2006/047136 WO2007067795A2 (en) | 2005-12-09 | 2006-12-08 | Methods for identifying and targeting tumor stem cells based on nuclear morphology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0619599A2 true BRPI0619599A2 (pt) | 2011-10-11 |
Family
ID=38099345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0619599-7A BRPI0619599A2 (pt) | 2005-12-09 | 2006-12-08 | método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090304662A1 (enExample) |
| EP (1) | EP1963490A2 (enExample) |
| JP (1) | JP2009518438A (enExample) |
| KR (1) | KR20080079302A (enExample) |
| CN (1) | CN101426903A (enExample) |
| AU (1) | AU2006321710A1 (enExample) |
| BR (1) | BRPI0619599A2 (enExample) |
| CA (1) | CA2632754A1 (enExample) |
| IL (1) | IL191746A0 (enExample) |
| RU (1) | RU2008127844A (enExample) |
| WO (1) | WO2007067795A2 (enExample) |
| ZA (1) | ZA200804973B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101209833B1 (ko) * | 2004-06-17 | 2012-12-07 | 메사추세츠 인스티튜트 오브 테크놀로지 | 핵 형태에 기초하여 줄기 세포를 동정하는 방법 |
| CN101720436A (zh) * | 2007-06-13 | 2010-06-02 | 麻省理工学院 | 用于通过靶向肿瘤干细胞的ssDNA复制中间物而抑制肿瘤生长的方法和药剂 |
| IT1392908B1 (it) | 2008-09-29 | 2012-04-02 | Italfarmaco Spa | Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative |
| US8217079B2 (en) | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
| KR20140016241A (ko) | 2010-10-25 | 2014-02-07 | 메사추세츠 인스티튜트 오브 테크놀로지 | 상처 치유 메타카리오틱 줄기 세포 및 그 사용방법 |
| US20140369934A1 (en) * | 2011-06-02 | 2014-12-18 | Massachusetts Institute Of Technology | dsRNA/DNA Hybrid Genome Replication Intermediate Of Metakaryotic Stem Cells |
| CN110118875B (zh) * | 2019-05-09 | 2020-08-28 | 量准(武汉)生命科技有限公司 | 一种人类唾液中c型反应性蛋白彩色成像的方法及装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| KR101209833B1 (ko) * | 2004-06-17 | 2012-12-07 | 메사추세츠 인스티튜트 오브 테크놀로지 | 핵 형태에 기초하여 줄기 세포를 동정하는 방법 |
-
2006
- 2006-12-08 KR KR1020087016673A patent/KR20080079302A/ko not_active Withdrawn
- 2006-12-08 EP EP06847546A patent/EP1963490A2/en not_active Withdrawn
- 2006-12-08 US US12/085,533 patent/US20090304662A1/en not_active Abandoned
- 2006-12-08 JP JP2008544572A patent/JP2009518438A/ja not_active Withdrawn
- 2006-12-08 WO PCT/US2006/047136 patent/WO2007067795A2/en not_active Ceased
- 2006-12-08 RU RU2008127844/13A patent/RU2008127844A/ru not_active Application Discontinuation
- 2006-12-08 CN CNA2006800525889A patent/CN101426903A/zh active Pending
- 2006-12-08 BR BRPI0619599-7A patent/BRPI0619599A2/pt not_active Application Discontinuation
- 2006-12-08 CA CA002632754A patent/CA2632754A1/en not_active Abandoned
- 2006-12-08 AU AU2006321710A patent/AU2006321710A1/en not_active Abandoned
-
2008
- 2008-05-27 IL IL191746A patent/IL191746A0/en unknown
- 2008-06-06 ZA ZA200804973A patent/ZA200804973B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2632754A1 (en) | 2007-06-14 |
| EP1963490A2 (en) | 2008-09-03 |
| JP2009518438A (ja) | 2009-05-07 |
| AU2006321710A1 (en) | 2007-06-14 |
| WO2007067795A2 (en) | 2007-06-14 |
| ZA200804973B (en) | 2009-11-25 |
| KR20080079302A (ko) | 2008-08-29 |
| IL191746A0 (en) | 2008-12-29 |
| US20090304662A1 (en) | 2009-12-10 |
| CN101426903A (zh) | 2009-05-06 |
| RU2008127844A (ru) | 2010-02-10 |
| WO2007067795A3 (en) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bacallao et al. | ATP depletion: a novel method to study junctional properties in epithelial tissues: cytoskeleton: I. Rearrangement of the actin | |
| CN102216777B (zh) | 通过检测细胞和合胞体的荧光来鉴别干细胞的方法 | |
| KR101209833B1 (ko) | 핵 형태에 기초하여 줄기 세포를 동정하는 방법 | |
| Wood et al. | Cytonemes with complex geometries and composition extend into invaginations of target cells | |
| JP5171945B2 (ja) | 腫瘍増殖を阻害する方法および薬剤 | |
| Kwon et al. | FILIP1L loss is a driver of aggressive mucinous colorectal adenocarcinoma and mediates cytokinesis defects through PFDN1 | |
| US20160146815A1 (en) | Method for screeing cancer metastasis inhibitor using culture of cells or spheroidically aggregated cells in which lysyl-trna synthetase is regulated to be expressed or unexpressed | |
| Lin et al. | Mechanotransduction pathways regulating YAP nuclear translocation under Yoda1 and vibration in osteocytes | |
| BRPI0619599A2 (pt) | método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente | |
| Vachon | Methods for assessing apoptosis and anoikis in normal intestine/colon and colorectal cancer | |
| Khine et al. | Epidermal growth factor receptor ligands enriched in follicular fluid exosomes promote oncogenesis of fallopian tube epithelial cells | |
| Jia et al. | Foxa2-dependent uterine glandular cell differentiation is essential for successful implantation | |
| Han et al. | The effects and mechanisms of myeloid differentiation protein 2 on intestinal mucosal permeability in mice with chronic colitis | |
| Zhang et al. | Identification and culture of functional salivary gland ductal epithelial cells | |
| Arora et al. | Isolation and Characterization of Extracellular Vesicles Derived from Ex Vivo Culture of Visceral Adipose Tissue | |
| Sun et al. | Inhibition of nucleostemin upregulates CDX2 expression in HT29 cells in response to bile acid exposure: implications in the pathogenesis of Barrett’s esophagus | |
| Fleszar | Follicular fluid, ovarian cortical inclusion cysts, and substrate curvature increase the cancerous progression of fallopian tube epithelial cells | |
| Underhill | Development of an Automated Computational Cell Tracking Tool for High-Throughput Screening of Cellular Migration in Exosome-Stimulated Wnt-PCP Signaling | |
| Chen et al. | Matrix-bound nanovesicles isolated from decellularized tumors as platforms for targeting parent tumor cells and tumor-associated stromal cells | |
| Zhang et al. | Myometrial extracellular vesicles promoted endometrial mesenchymal stem/stromal cells to self-renewal via jag1-mediated notch signaling | |
| Gant | Understanding Extracellular Matrix Alterations in High Grade Serous Ovarian Cancer | |
| WO2025245229A1 (en) | Regulating mucus production | |
| Momeni et al. | Possible Role of N-Methyl-D-Aspartate Glutamate Receptors in The Induction of Acrosome Reaction in Human Sperm. | |
| Li et al. | Uterine stromal Erbb3-Igf1 signaling is critical to functional gland development conducive to implantation | |
| 김용률 | Studies on the Oncogenesis of Ewings Sarcoma Mediated by Phase Separation of ARID1A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/711 (2006.01), A61K 31/7115 (2006.01), A61 |